Biomarkers of Bronchial Asthma.

Asthma is a complex disease with a variable course. Efforts to identify biomarkers to predict asthma severity, the course of disease and response to treatment have not been very successful so far. Biomarker research has expanded greatly with the advancement of molecular research techniques. An ideal biomarker should be suitable to identify the disease as well the specific endotype/phenotype, useful in the monitoring of the disease and to determine the prognosis, easily to obtain with minimum discomfort or risk to the patient. An ideal biomarker should be suitable to identify the disease as well the specific endotype/phenotype, useful in the monitoring of the disease and to determine the prognosis, easily to obtain with minimum discomfort or risk to the patient - exhaled breath analysis, blood cells and serum biomarkers, sputum cells and mediators and urine metabolites could be potential biomarkers of asthma bronchiale. Unfortunately, at the moment, an ideal biomarker doesn't exist and the overlap between the biomarkers is a reality. Using panels of biomarkers could improve probably the identification of asthma endotypes in the era of precision medicine.

[1]  A. Calkovska,et al.  The effect of pulmonary surfactant on the airway smooth muscle after lipopolysaccharide exposure and its mechanisms. , 2019, Physiological research.

[2]  A. Tiotiu.  Biomarkers in asthma: state of the art , 2018, Asthma Research and Practice.

[3]  M. Grayson,et al.  Advances in asthma in 2017: Mechanisms, biologics, and genetics , 2018, The Journal of allergy and clinical immunology.

[4]  M. Hew,et al.  Recent developments and highlights in biomarkers in allergic diseases and asthma , 2018, Allergy.

[5]  C. Brightling,et al.  Asthma , 2018, The Lancet.

[6]  Gerta Rücker,et al.  A novel statistical model for analyzing data of a systematic review generates optimal cutoff values for fractional exhaled nitric oxide for asthma diagnosis. , 2017, Journal of clinical epidemiology.

[7]  G. Canonica,et al.  Asthma: personalized and precision medicine , 2017, Current opinion in allergy and clinical immunology.

[8]  I. Tonhajzerova,et al.  Nasal nitric oxide in healthy adults - reference values and affecting factors. , 2017, Physiological research.

[9]  T. Buday,et al.  Physiology of nitric oxide in the respiratory system. , 2017, Physiological research.

[10]  N. Hanania,et al.  Predictive Biomarkers for Asthma Therapy , 2017, Current Allergy and Asthma Reports.

[11]  M. Weatherall,et al.  Longitudinal variation of serum periostin levels in adults with stable asthma. , 2017, The Journal of allergy and clinical immunology.

[12]  I. Sayers,et al.  Airway and peripheral urokinase plasminogen activator receptor is elevated in asthma, and identifies a severe, nonatopic subset of patients , 2017, Allergy.

[13]  S. Madhunapantula,et al.  Evaluation of inflammatory markers interleukin-6 (IL-6) and matrix metalloproteinase-9 (MMP-9) in asthma , 2017, The Journal of asthma : official journal of the Association for the Care of Asthma.

[14]  D. Postma,et al.  Airway and peripheral uPAR is elevated in asthma, and identifies a severe, non-atopic subset of patients , 2016 .

[15]  Gerta Rücker,et al.  Accuracy of FENO for diagnosing asthma: a systematic review , 2016, Thorax.

[16]  F. Ozkinay,et al.  MicroRNA expression profiling in children with different asthma phenotypes , 2016, Pediatric pulmonology.

[17]  J. Vandesompele,et al.  Asthma inflammatory phenotypes show differential microRNA expression in sputum. , 2016, The Journal of allergy and clinical immunology.

[18]  C. Porsbjerg,et al.  Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study , 2016, Respiratory Research.

[19]  A. Fitzpatrick.  Biomarkers of asthma and allergic airway diseases. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  M. Henket,et al.  Asthma Control and Sputum Eosinophils: A Longitudinal Study in Daily Practice. , 2015, The journal of allergy and clinical immunology. In practice.

[21]  S. Hazen,et al.  Biomarker-based asthma phenotypes of corticosteroid response. , 2015, The Journal of allergy and clinical immunology.

[22]  T. Shimoda,et al.  Serum high-sensitivity C-reactive protein can be an airway inflammation predictor in bronchial asthma. , 2015, Allergy and asthma proceedings.

[23]  Tzu-chin Wu,et al.  Differences in IL-8 in serum and exhaled breath condensate from patients with exacerbated COPD or asthma attacks. , 2014, Journal of the Formosan Medical Association = Taiwan yi zhi.

[24]  W. Busse,et al.  Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. , 2014, The Journal of allergy and clinical immunology.

[25]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[26]  James J. Lee,et al.  Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia , 2013, Allergy.

[27]  Jing Gao,et al.  Differences in plasma and sputum biomarkers between COPD and COPD–asthma overlap , 2013, European Respiratory Journal.

[28]  Q. Jöbsis,et al.  Exhaled volatile organic compounds predict exacerbations of childhood asthma in a 1-year prospective study , 2013, European Respiratory Journal.

[29]  J. Debley,et al.  Airway epithelial cells from asthmatic children differentially express proremodeling factors. , 2012, The Journal of allergy and clinical immunology.

[30]  L. Shek,et al.  Eosinophil cationic protein: is it useful in asthma? A systematic review. , 2007, Respiratory medicine.

[31]  S. Willsie.  An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications , 2012 .